Annovis Bio, Inc. (ANVS) — SEC Filings
Annovis Bio, Inc. (ANVS) — 49 SEC filings. Latest: 8-K (Mar 25, 2026). Includes 38 8-K, 6 10-Q, 2 DEF 14A.
View Annovis Bio, Inc. on SEC EDGAR
Overview
Annovis Bio, Inc. (ANVS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 25, 2026: Annovis Bio, Inc. filed an 8-K on March 25, 2026, reporting events from March 23, 2026, under Item 5.02, which typically covers changes in directors or officers and their compensation. This filing indicates a significant corporate governance or executive compensation event, which could impact the co
Sentiment Summary
Across 49 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 43 neutral, 2 mixed. The dominant filing sentiment for Annovis Bio, Inc. is neutral.
Filing Type Overview
Annovis Bio, Inc. (ANVS) has filed 38 8-K, 6 10-Q, 1 DEFA14A, 2 DEF 14A, 2 10-K with the SEC between Mar 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (49)
Risk Profile
Risk Assessment: Of ANVS's 47 recent filings, 3 were flagged as high-risk, 21 as medium-risk, and 23 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $-7,262,658 |
| EPS | $-0.37 |
| Debt-to-Equity | 0.31 |
| Cash Position | $15,286,399 |
| Operating Margin | -100.0% |
| Total Assets | $17,188,961 |
| Total Debt | $4,032,797 |
Key Executives
- Dr. Michael J. McVicar
- Dr. Maria L. Maccecchini
- Dr. Joseph E. Please
- Dr. Maria Maccecchini
- Dr. Alan Ezekowitz
- Dr. Alan S. Roeder
- Maria Maccecchini
Industry Context
Annovis Bio operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on treatments for neurodegenerative diseases. This field is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Companies in this space often rely on external financing and strategic partnerships to advance their pipelines.
Top Tags
financial-reporting (7) · 8-K (7) · 8-k (5) · financials (5) · corporate-governance (4) · material-definitive-agreement (4) · sec-filing (4) · executive-compensation (3) · leadership-change (3) · material-agreement (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash and Cash Equivalents | $15.3M | Increased from $10.5M at Dec 31, 2024, but still insufficient to fund operations for one year. |
| Net Loss (9 months) | $19.0M | Slightly higher than $18.7M in prior year, indicating continued burn rate. |
| Accumulated Deficit | $153.9M | Highlights significant historical losses and ongoing financial challenges. |
| Proceeds from Stock Issuance | $21.4M | Primary source of capital, crucial for current liquidity but dilutive. |
| R&D Expenses (Q3) | $6.3M | Increased from $2.7M in Q3 2024, showing accelerated clinical development. |
| Outstanding Common Shares | 26,502,889 | As of November 12, 2025, reflecting recent equity issuances and dilution. |
| SEC File Number | 001-39202 | Identifies the company's filing with the SEC |
| IRS Employer Identification No. | 26-2540421 | Company's tax identification number |
| Annual Salary | $450,000 | for the new Chief Medical Officer, Dr. Joseph E. Please. |
| Revenue | $0 | No revenue reported for Q2 2025 or YTD 2025, indicating clinical-stage status. |
| Net Loss (Q2 2025) | $10.5M | Increased from $9.5M in Q2 2024, reflecting higher operational costs. |
| Net Loss (YTD 2025) | $20.1M | Increased from $18.5M in YTD 2024, showing a widening loss trend. |
| R&D Expenses (Q2 2025) | $8.1M | Up from $7.3M in Q2 2024, driven by ongoing clinical trials for ANVS401 and ANVS301. |
| G&A Expenses (Q2 2025) | $2.4M | Increased from $2.2M in Q2 2024, indicating higher administrative overhead. |
| Total Assets | 10519933 | Reported for the fiscal year 2024 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Annovis Bio, Inc. (ANVS)?
Annovis Bio, Inc. has 49 recent SEC filings from Mar 2024 to Mar 2026, including 38 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ANVS filings?
Across 49 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 43 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Annovis Bio, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Annovis Bio, Inc. (ANVS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Annovis Bio, Inc.?
Key financial highlights from Annovis Bio, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ANVS?
The investment thesis for ANVS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Annovis Bio, Inc.?
Key executives identified across Annovis Bio, Inc.'s filings include Dr. Michael J. McVicar, Dr. Maria L. Maccecchini, Dr. Joseph E. Please, Dr. Maria Maccecchini, Dr. Alan Ezekowitz and 2 others.
What are the main risk factors for Annovis Bio, Inc. stock?
Of ANVS's 47 assessed filings, 3 were flagged high-risk, 21 medium-risk, and 23 low-risk.
What are recent predictions and forward guidance from Annovis Bio, Inc.?
Forward guidance and predictions for Annovis Bio, Inc. are extracted from SEC filings as they are enriched.